PMDA announcement: recommendations on perioperative administration of andexanet alfa
「関係学会等からの医薬品の適正使用に関するお知らせ」に「アンデキサネット アルファの周術期投与に関する提言」を掲載しました
Published: 2025-07-22 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2025-07-22, the Pharmaceuticals and Medical Devices Agency (PMDA) announced that it had posted recommendations on perioperative administration of andexanet alfa. The recommendations were added to its notices from relevant academic societies and other organizations on the proper use of medicines.
Business Impact
Healthcare professionals involved in perioperative administration of andexanet alfa may find the recommendations relevant to its use, but the title does not disclose the specific recommendations.
Recommended Action
Review of the official Japanese posting and linked recommendations would help clarify their scope and the advice on perioperative administration.